Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > fda max

: 1400 mg q4w

or 50 mg/d

or 600 mg/d

Use the filters below to narrow your results.

None (2) · Benzonatate (1) · Cefdinir (1) · Mirabegron (1)

Kisunla (1) · Myrbetriq (1) · Omnicef (discontinued in US under brand); mostly generic (1) · Quviviq (1) · Tessalon, Zonatuss (1)

Anti-amyloid beta (Aβ) monoclonal antibody (1) · Dual orexin receptor antagonist (DORA) (1) · targets pyroglutamated Aβ in plaques (1) · [[:Category:Antitussives|Antitussive]] (1) · [[:Category:Beta-3_agonists|β3 adrenergic agonist]] (1) · [[:Category:Beta-lactam_antibiotics|β-lactam antibiotic]] (1) · [[:Category:Cephalosporins|Cephalosporin (third-generation)]] (1) · [[:Category:Overactive_bladder_medications|Overactive bladder medication]] (1)

None (4) · '"`UNIQ--vote-00000015-QINU`"' Pediatric ingestion (capsule chewed or punctured) releases the free local anesthetic and causes seizures, cardiac arrhythmia, and death'"`UNIQ--ref-00000016-QINU`"'. (1)

Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1) · Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022) (1) · '"`UNIQ--vote-00000017-QINU`"' (1) · '"`UNIQ--vote-000009DF-QINU`"', '"`UNIQ--vote-000009E0-QINU`"', '"`UNIQ--vote-000009E1-QINU`"', '"`UNIQ--vote-000009E2-QINU`"', '"`UNIQ--vote-000009E3-QINU`"' (1) · '"`UNIQ--vote-00000C4C-QINU`"', '"`UNIQ--vote-00000C4D-QINU`"' (1)

100-200 mg PO TID (max 600 mg/d) (1) · 25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) · 25 mg PO once daily; titrate to 50 mg after 4-8 weeks if needed (1) · 300 mg PO BID, or 600 mg PO once daily, ×5-10 days; pediatric 14 mg/kg/d (1) · 700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance (1)

100, 150, 200 mg liquid-filled capsules ("perles") (1) · 25 mg, 50 mg tablets (1) · 25, 50 mg ER tablets; 8 mg/mL granules for oral suspension (Myrbetriq Granules, pediatric) (1) · 300 mg capsules; 125, 250 mg/5 mL suspension (1) · 350 mg/20 mL vial for IV infusion (1)

IV infusion every 4 weeks (1) · Oral (3) · Oral (swallow whole) (1)

15-20 minutes (1) · Amyloid PET clearance within months; cognitive benefit over 18 months (1) · Hours (1) · Symptom improvement within weeks (1) · ~30 min (1)

12-24 hours (1) · 24 hours (1) · 3-8 hours (1) · Treatment can be discontinued upon achieving amyloid clearance (1) · ~7-8 hours (1)

Not well characterized'"`UNIQ--ref-00000018-QINU`"' (1) · ~1.7 hours'"`UNIQ--ref-000009E4-QINU`"' (1) · ~12.1 days (1) · ~50 hours'"`UNIQ--ref-00000C4E-QINU`"' (1) · ~8 hours (shorter than suvorexant and lemborexant) (1)

100% (IV) (1) · 16-21% capsule, 25% suspension (oral; iron and antacids reduce absorption substantially)'"`UNIQ--ref-000009E5-QINU`"' (1) · 25 mg: ~29%; 50 mg: ~35%; food reduces absorption'"`UNIQ--ref-00000C4F-QINU`"' (1) · Not well characterized'"`UNIQ--ref-00000019-QINU`"' (1) · ~62% (1)

Generally considered safe in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Limited data (1) · Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Limited data; avoid (1) · Limited human data; animal reproductive studies not conducted<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

Rx, Schedule IV (US) (1) · Rx; ARIA monitoring required (1) · [[USLegal:Prescription only|Rx-only]] in US (3)

Showing below up to 5 results in range #1 to #5.

B

Benzonatate

C

Cefdinir

D

M

Mirabegron

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"